Clinical Trial Update: Study of Immune Response Modifier in the Treatment of Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of an immune response modifier in hematologic malignancies has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Immune Response Modifier

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2010-05-05